Universiteit Leiden

Can-fite Biopharma Ltd.

Ad Ijzerman

Erica Van Tilburg

The present invention concerns novel C2,5'-disubstituted and N,C2,5&#x2032;-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.

[object Object]

Novel C2,8-disubstituted adenosine derivatives disclosed herein have been found to be potent adenosine receptor agonists, in particular for the A2A receptor. The said compounds have biological activity against conditions such as hypertension, ischemic heart disease, ischemic brain disease, psychosis and wound healing. Further, the invention also discloses a process for the preparation of such compounds and pharmaceutical compositions comprising them.

C2,8-disubstituted adenosine derivatives and their different uses

The present invention concerns novel C2,5'-disubstituted and N&#x2032;,C2,5&#x2032;-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.

Growing community of inventors

Haarlem, Netherlands

Ad Ijzerman